Isomorphic Labs, the AI drug discovery company spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and existing backers including Alphabet’s GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also participating. The round follows a $2.1 billion Series B in May and is the company’s first raise since founder Demis Hassabis stepped back as head of DeepMind to focus on drug discovery, moving into a chairman role there.
The company said the new capital will fund further development of its AI drug design engine and expansion into more areas of medicine as it moves candidates toward clinical trials. Isomorphic said its programs have produced positive preclinical results in oncology and immunology, and it has research deals in place with Eli Lilly, Novartis and Johnson & Johnson. The company did not disclose its valuation; Bloomberg reported earlier this month that it had been seeking funding at a $50 billion valuation.